An2 Therapeutics, INC Form 4 insider transactions

Joshua Eizen, Chief Legal Officer of AN2 Therapeutics, reports the acquisition of 60,000 shares of common stock through a restricted stock unit (RSU) grant and adjustments to existing RSU holdings.

Director Robin Shane Readnour acquired stock options in AN2 Therapeutics, according to a recent SEC Form 4 filing.

Director Gilbert Lynn Marks of AN2 Therapeutics, Inc. reports the acquisition of stock options.

Director Margaret M. FitzPatrick of AN2 Therapeutics reports the acquisition of stock options.

Director Kabeer Aziz of AN2 Therapeutics, Inc. was granted stock options for 64,503 shares on June 19, 2024, according to a Form 4 filing.

Director Joseph Zakrzewski of AN2 Therapeutics, Inc. was granted stock options on June 19, 2024, according to a recent SEC filing.

Director Melvin K. Spigelman of AN2 Therapeutics, Inc. reports the acquisition of stock options for 64,503 shares of common stock.

Patricia A. Martin, a director of AN2 Therapeutics, was granted stock options to purchase 64,503 shares of common stock on June 19, 2024.

Director Stephanie Wong of AN2 Therapeutics, Inc. reports the acquisition of stock options.

Paul Eckburg, Chief Medical Officer of AN2 Therapeutics, amends a previous SEC Form 4 filing to clarify the vesting schedule of restricted stock units.

Lucy Day, CFO of AN2 Therapeutics, filed an amendment to a previous Form 4, detailing the vesting schedule for her restricted stock units.

Joshua M. Eizen, Chief Legal Officer of AN2 Therapeutics, reports an amendment to the vesting schedule of his restricted stock units.

Kevin Michael Krause, Chief Strategy Officer of AN2 Therapeutics, amends a previous Form 4 filing to clarify the vesting schedule for restricted stock units.

Sanjay Chanda, Chief Development Officer of AN2 Therapeutics, amends a previous SEC Form 4 filing to clarify the vesting schedule of restricted stock units.

Eric Easom, CEO of AN2 Therapeutics, amends a previous SEC Form 4 filing to clarify the vesting schedule of restricted stock units.

Lucy Day, CFO of AN2 Therapeutics, reports acquisition of restricted stock units and stock options, along with adjusted holdings including shares purchased under the employee stock purchase plan.

Joshua M. Eizen, Chief Legal Officer of AN2 Therapeutics, reports the acquisition of restricted stock units and stock options.

Kevin Michael Krause, Chief Strategy Officer of AN2 Therapeutics, reports the acquisition of 30,000 shares of common stock and 60,000 stock options.

Chief Development Officer Sanjay Chanda of AN2 Therapeutics reports acquisition of stock and stock options, along with adjustments to previously held shares.

Paul Eckburg, Chief Medical Officer of AN2 Therapeutics, reports acquisition of stock options and restricted stock units.

Eric Easom, CEO of AN2 Therapeutics, reports acquisition and disposal of common stock, along with a new stock option grant.